Millions quietly endure the frustration of chronic pain or debilitating conditions that limit life's greatest joys like sharing adventures with loved ones, pursuing passions without hesitation, or simply moving with ease and confidence. Yet amid these challenges, groundbreaking advancements are emerging, tapping into the body's remarkable ability to heal itself and offering renewed possibilities for lasting wellness.

This is the promise delivered by R3 Stem Cell, the world's foremost leader in regenerative medicine. For over a decade, R3 has pioneered stem cell and exosome therapies across more than 80 Centers of Excellence in eight countries, enabling patients to often avoid surgery, repair damaged tissues, and reclaim vibrant, active lives.

R3 Stem Cell’s experts utilize over 25 personalized protocols, including options for autologous sources like bone marrow, adipose tissue, or platelet-rich plasma, alongside donor-derived Wharton’s jelly, umbilical cord blood, and exosomes, all sourced from ISO-certified, rigorously regulated labs, thus setting the benchmark for trust and innovation.

Having completed over 27,000 procedures with a remarkable 85% patient satisfaction rate, R3 surpasses competitors in safety, effectiveness, and affordability. Through free consumer guides, master classes, and dedicated education, it ensures patients make empowered decisions, steering clear of inferior options.Committed to global availability, clinical excellence, and affordability, R3 advances groundbreaking research while helping individuals reduce pain, boost function, and stay active on their terms, from arthritis and neuropathy to autoimmune diseases, neurological challenges, and beyond.

In an exclusive interview with CIO Bulletin, David Greene, Founder and CEO of R3 Stem Cell, offered inspiring insights into the company’s mission. He explained how his dedicated team of experts focuses on authentic healing rather than mere symptom management, delivering real treatment options, renewed freedom of movement, and the life-changing opportunity for patients to reclaim pain-free lives.

Interview Highlights

Could you walk us through the inception of R3 Stem Cell? What inspired the founding of the company, and how has its mission evolved over the past decade to become a global leader in regenerative therapies?

I started R3 Stem Cell while I was enrolled in the Executive MBA program at Arizona State University, initially as a mock company for an entrepreneurship class. The feedback from my professors was exceptional, so I decided to turn it into a real company. That was 14 years ago, and since then, the mission has evolved into providing the highest-quality, most effective, and affordable regenerative therapies in the world.

The Mission resonates in every country R3 enters, and that has propelled R3 to become the world’s largest provider of regenerative therapies.

In brief, how would you describe R3 Stem Cell’s service offerings, and what distinct clinical, ethical, or scientific advantages make them stand out globally?

There is significant responsibility in being the world’s largest provider of regenerative therapies. We must ensure that our biologics are not only ethically sourced, but also held to the highest safety standards worldwide so patients are not put at risk. We see laboratories and clinics around the world that ‘cut corners’ when offering regenerative procedures, and this is a huge disservice to patients.

From a clinical perspective, we benefit from using evidence-based medicine to guide our protocols. In addition, as a high-volume player in the regenerative space, our global clinics provide extensive information that helps us develop what I call ‘Best Practice Protocols.’ This combination benefits patients tremendously and gives us a unique competitive advantage in helping them obtain desired results.

I have also built two GMP-compliant tissue processing labs to control all aspects of the biologics used. Our PhDs have unparalleled attention to detail, along with an innovative drive to ensure that patients receive only first-rate, extremely safe products.

Customization appears to be central to your treatment philosophy. How do R3’s individualized protocols improve patient outcomes compared to “one-size-fits-all” regenerative solutions?

No other regenerative company has incorporated the entire vertical into its business model. We control tissue processing because we built our own labs. This includes quality and safety, so patients can rest assured that we would never do anything that could negatively affect their safety or outcomes.

When it comes to treatment protocols, R3 is in a unique position to develop customized options. This includes evidence-based protocols drawn from the vast amount of peer-reviewed research now available. In addition, the extensive number of global procedures performed by our clinics and affiliates allows our teams to engage in robust peer-to-peer discussions about what has proven to work effectively across a wide range of conditions.

By applying our knowledge from top to bottom, we have developed a significant number of innovations, including IntelliCell, the Regenerative Trifecta, StemImplant, and upcoming advancements that continuously improve patient outcomes.

With over 27,000 procedures performed globally and an 85% patient satisfaction rate, what operational and clinical standards enable R3 to maintain such consistency across geographies?

Regenerative procedures are currently not covered by health insurance companies. As a result, we know that patients deserve an exceptional experience for the hard-earned dollars they spend. In addition, care must be well organized, as patients often change locations for future treatments, and our consultants need access to both current and past imaging and medical records.

Because of this, R3 has invested millions in its technology stack over the past decade. Our globally distributed team can now view incoming patient leads, communicate with them through our software, schedule consultations and treatments, manage finances, and store all electronic medical records in an encrypted, HIPAA-compliant database.

Along with a technology platform that enables global coordination, we have established strong education and training programs for all consultants, Medical Directors, patient concierges, and front-office personnel to ensure consistent standards of care. This platform continues to evolve, as the field of regenerative medicine advances rapidly!

The regenerative medicine space has seen its share of misinformation. How does R3 actively educate patients to help them distinguish authentic stem cell therapies from misleading or sub-optimal alternatives?

For the past ten years, patient and provider education has been the cornerstone of R3’s approach. As the company’s CEO, my main role has been to stay up to date on regenerative medicine research and provide accurate educational information to patients.

Unfortunately, many companies focus on disseminating myths or inaccuracies to promote their own agendas. I prefer to focus on facts, even if they do not serve our mission or current agenda.

Patients deserve accurate information to make their own healthcare decisions. In addition, R3 focuses on delivering educational information in layman’s terms. After all, what good is knowledge if patients can’t understand what you’re saying?

As a nominee for “Stem Cell Innovation of the Year 2026”, what groundbreaking advancements has R3 Stem Cell made in the past year that exemplify innovation in regenerative medicine, particularly in areas like exosome therapy or the use of Wharton's Jelly from umbilical cord tissue?

I can provide an answer, but I always need to keep our ‘secret sauce’ so our competitors continue guessing why we get such amazing outcomes. When we trademarked the Regenerative Trifecta, no other company was providing the combination of stem cells, exosomes, and PRP in such a particular manner for improved outcomes.

When studies come out showing benefits, our team takes notice. We are always innovating if we think patients will benefit, while keeping safety foremost in mind. We know that exosomes are amazing, but often not able to provide the complete benefit by themselves. So our team knows what combinations work best, which is why our treatments are individualized so often.

Regenerative medicine is so exciting because the results have been great, the treatments have been extremely safe, while at the same time the window is just opening!

Looking ahead, what are R3 Stem Cell's strategic goals for the next five years? How do you envision expanding your global network of over 45 Centers of Excellence while maintaining your commitment to affordability, safety, and high patient satisfaction rates?

My goal has been for R3 Stem Cell to be the ‘Marriott’ of regenerative therapies, and we are well on our way to achieving that. Patients shouldn’t have to fly halfway across the world or pay a ridiculous amount to receive the regenerative therapies they need. R3 is in a unique position to continue controlled growth to achieve this goal.

My team keeps me in check when it comes to growth. There are parameters we must meet at each location to ensure quality controls, patient outcomes, and safety standards are upheld. I never want to compromise those. With a much higher volume than any other company and control over the entire supply chain, we are able to keep treatments as affordable as possible for patients and their families.

The Visionary Leader Transforming Lives through Regenerative Medicine

David Greene, MD, PhD, MBA, Founder and CEO, started R3 Stem Cell 14 years ago and has remained at the forefront of regenerative medicine while overseeing R3’s growth into the world’s largest provider of regenerative therapies, and the largest provider of educational information for patients and their families.

With over 1,000 YouTube videos, a Stem Cell MasterClass, 30 Consumer Guides, a podcast, weekly provider trainings, and the upcoming book Stem Cell Genius, Dr. Greene leads the way globally with up-to-date, accurate regenerative education.

Dr. Greene’s background was in orthopedics before shifting to the business side of medicine over 15 years ago. He has since earned an MBA along with a PhD in Stem Cell Biology. According to him, “The most satisfaction I receive now comes from patient success stories. We have hundreds of them from around the world, covering over FIFTY different conditions! It’s what drives me and our team of over 100 individuals worldwide… tremendous patient outcomes.”

“My goal has been for R3 Stem Cell to be the ‘Marriott’ of regenerative therapies. By combining the highest treatment volume with full control over our supply chain, we ensure that every procedure is safe, effective, and as affordable as possible for patients and their families.”